![Gabriel Brooks](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gabriel Brooks
Chief Tech/Sci/R&D Officer at
SOLID BIOSCIENCES INC.
Net worth: 857 084 $ as of 31/08/2026
Profile
Gabriel Brooks is Chief Medical Officer at Solid Biosciences, Inc. since 2023.
Formerly, Dr. Brooks was Vice President-Research & Development at 4D Molecular Therapeutics, Inc. from 2018 to 2020.
Education includes undergraduate studies at Carnegie Mellon University, a doctorate from Cornell University, and graduate studies at the University of California.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/03/2026 | 89,466 ( 0.08% ) | 857 084 $ | 31/08/2026 |
Gabriel Brooks active positions
| Companies | Position | Start |
|---|---|---|
| SOLID BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 02/10/2023 |
Former positions of Gabriel Brooks
| Companies | Position | End |
|---|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2020 |
Training of Gabriel Brooks
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
31
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Carnegie Mellon University
 Carnegie Mellon University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California
 University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
4D Molecular Therapeutics, Inc.
 4D Molecular Therapeutics, Inc. BiotechnologyHealth Technology Designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions | Health Technology |
Solid Biosciences, Inc.
 Solid Biosciences, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that develops treatments through gene therapy for patients with duchenne disease | Health Technology |
- Stock Market
- Insiders
- Gabriel Brooks
